Q-omics provides the consensus-scored RPS3AP33 profile across patient tissues and cancer cell-line models. RPS3AP33 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RPS3AP33 is differentially expressed in 3, with the highest sampling consensus in COAD. Additionally, RPS3AP33 RNA expression shows 4,382 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight HNSC, COAD, and STAD as cancer lineages where RPS3AP33 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS3AP33 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS3AP33 survival associations across molecular data types. RPS3AP33 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS3AP33 RNA expression–survival associations across cancer types. High RPS3AP33 expression shows unfavorable associations in HNSC, KIRC, ACC and UVM, but favorable associations in CESC and GBM. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .015). Together, the overview and detailed table identify HNSC as the clearest survival context for RPS3AP33 RNA expression.
This table summarizes RPS3AP33 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPS3AP33. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS3AP33 shows lower tumor expression in COAD and UCEC and higher tumor expression in KIRP. The COAD box plot shows higher RPS3AP33 RNA expression in normal versus tumor tissue (log2 FC = −0.033, t-test p = .016).
This table shows molecular features associated with RPS3AP33 in patient tissues and cancer cell lines. In patient samples, RPS3AP33 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
